These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 27180307)

  • 1. Repositioning of drugs for intervention in tumor progression and metastasis: Old drugs for new targets.
    Mudduluru G; Walther W; Kobelt D; Dahlmann M; Treese C; Assaraf YG; Stein U
    Drug Resist Updat; 2016 May; 26():10-27. PubMed ID: 27180307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds.
    Würth R; Thellung S; Bajetto A; Mazzanti M; Florio T; Barbieri F
    Drug Discov Today; 2016 Jan; 21(1):190-199. PubMed ID: 26456577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repositioning of proton pump inhibitors in cancer therapy.
    Lu ZN; Tian B; Guo XL
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):925-937. PubMed ID: 28861639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: An underestimated truth.
    Yadav V; Talwar P
    Biomed Pharmacother; 2019 Mar; 111():934-946. PubMed ID: 30841473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational drug repositioning for cancer therapeutics.
    Jiao M; Liu G; Xue Y; Ding C
    Curr Top Med Chem; 2015; 15(8):767-75. PubMed ID: 25732789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
    Carrella D; Manni I; Tumaini B; Dattilo R; Papaccio F; Mutarelli M; Sirci F; Amoreo CA; Mottolese M; Iezzi M; Ciolli L; Aria V; Bosotti R; Isacchi A; Loreni F; Bardelli A; Avvedimento VE; di Bernardo D; Cardone L
    Oncotarget; 2016 Sep; 7(37):58743-58758. PubMed ID: 27542212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs are not enough‑drug repositioning in oncology: An update.
    Armando RG; Mengual Gómez DL; Gomez DE
    Int J Oncol; 2020 Mar; 56(3):651-684. PubMed ID: 32124955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current state and outlook for drug repositioning anticipated in the field of ovarian cancer.
    Kobayashi Y; Banno K; Kunitomi H; Tominaga E; Aoki D
    J Gynecol Oncol; 2019 Jan; 30(1):e10. PubMed ID: 30479094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and redox capacity.
    Fan XX; Pan HD; Li Y; Guo RJ; Leung EL; Liu L
    Pharmacol Ther; 2018 Nov; 191():148-161. PubMed ID: 29953901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug repositioning in cancer: The current situation in Japan.
    Masuda T; Tsuruda Y; Matsumoto Y; Uchida H; Nakayama KI; Mimori K
    Cancer Sci; 2020 Apr; 111(4):1039-1046. PubMed ID: 31957175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scaffold Repurposing of Old Drugs Towards New Cancer Drug Discovery.
    Chen H; Wu J; Gao Y; Chen H; Zhou J
    Curr Top Med Chem; 2016; 16(19):2107-14. PubMed ID: 26881709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revisiting Non-Cancer Drugs for Cancer Therapy.
    Yang EJ; Wu C; Liu Y; Lv J; Sup Shim J
    Curr Top Med Chem; 2016; 16(19):2144-55. PubMed ID: 26881712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why does cancer therapy lack effective anti-metastasis drugs?
    Weber GF
    Cancer Lett; 2013 Jan; 328(2):207-11. PubMed ID: 23059758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathway-Based Drug Repositioning for Cancers: Computational Prediction and Experimental Validation.
    Iwata M; Hirose L; Kohara H; Liao J; Sawada R; Akiyoshi S; Tani K; Yamanishi Y
    J Med Chem; 2018 Nov; 61(21):9583-9595. PubMed ID: 30371064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts.
    Lappano R; Maggiolini M
    Drugs; 2017 Jun; 77(9):951-965. PubMed ID: 28401445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs.
    Bhattarai D; Singh S; Jang Y; Hyeon Han S; Lee K; Choi Y
    Curr Top Med Chem; 2016; 16(19):2156-68. PubMed ID: 26881715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug repositioning: re-investigating existing drugs for new therapeutic indications.
    Padhy BM; Gupta YK
    J Postgrad Med; 2011; 57(2):153-60. PubMed ID: 21654146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting signal transduction pathways of cancer stem cells for therapeutic opportunities of metastasis.
    Iqbal W; Alkarim S; AlHejin A; Mukhtar H; Saini KS
    Oncotarget; 2016 Nov; 7(46):76337-76353. PubMed ID: 27486983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.